Mitochondrial hepatopathy:Anticipated difficulties in management of fatty acid oxidation defects and urea cycle defects

被引:0
作者
Aathira Ravindranath [1 ]
Moinak Sen Sarma [2 ]
机构
[1] Division of Pediatric Gastroenterology, Institute of Gastrointestinal Sciences, Apollo BGS Hospitals
[2] Sanjay Gandhi Postgraduate Institute of Medical Sciences
关键词
D O I
暂无
中图分类号
R575 [肝及胆疾病];
学科分类号
1002 ; 100201 ;
摘要
Fatty acid oxidation defects(FAOD) and urea cycle defects(UCD) are among the most common metabolic liver diseases. Management of these disorders is dotted with challenges as the strategies differ based on the type and severity of the defect. In those with FAOD the cornerstone of management is avoiding hypoglycemia which in turn prevents the triggering of fatty acid oxidation. In this review, we discuss the role of carnitine supplementation, dietary interventions, newer therapies like triheptanoin, long-term treatment and approach to positive newborn screening. In UCD the general goal is to avoid excessive protein intake and indigenous protein breakdown. However, one size does not fit all and striking the right balance between avoiding hyperammonemia and preventing deficiencies of essential nutrients is a formidable task. Practical issues during the acute presentation including differential diagnosis of hyperammonemia, dietary dilemmas, the role of liver transplantation, management of the asymptomatic individual and monitoring are described in detail. A multi-disciplinary team consisting of hepatologists, metabolic specialists and dieticians is required for optimum management and improvement in quality of life for these patients.
引用
收藏
页码:180 / 194
页数:15
相关论文
共 32 条
[21]  
Amino Acid Profiles in Patients with Urea Cycle Disorders at Admission to Hospital due to Metabolic Decompensation[J] . Rodney S,Boneh A.JIMD reports . 2013
[22]  
Systemic primary carnitine deficiency: an overview of clinical manifestations, diagnosis, and management[J] . Magoulas Pilar L,El-Hattab Ayman W.Orphanet journal of rare diseases . 2012 (1)
[23]   Early Clinical Manifestations and Eating Patterns in Patients with Urea Cycle Disorders [J].
Gardeitchik, Thatjana ;
Humphrey, Maureen ;
Nation, Judy ;
Boneh, Avihu .
JOURNAL OF PEDIATRICS, 2012, 161 (02) :328-332
[24]  
Suggested guidelines for the diagnosis and management of urea cycle disorders[J] . H?berle Johannes,Boddaert Nathalie,Burlina Alberto,Chakrapani Anupam,Dixon Marjorie,Huemer Martina,Karall Daniela,Martinelli Diego,Crespo Pablo Sanjurjo,Santer René,Servais Aude,Valayannopoulos Vassili,Lindner Martin,Rubio Vicente,Dionisi-Vici Carlo.Orphanet journal of rare diseases . 2012 (1)
[25]   Gene Transfer for Inherited Metabolic Disorders of the Liver: Immunological Challenges [J].
Gordts, Stephanie C. ;
Van Craeyveld, Eline ;
Jacobs, Frank ;
De Geest, Bart .
CURRENT PHARMACEUTICAL DESIGN, 2011, 17 (24) :2542-2549
[26]   Current issues regarding treatment of mitochondrial fatty acid oxidation disorders [J].
Spiekerkoetter, Ute ;
Bastin, Jean ;
Gillingham, Melanie ;
Morris, Andrew ;
Wijburg, Frits ;
Wilcken, Bridget .
JOURNAL OF INHERITED METABOLIC DISEASE, 2010, 33 (05) :555-561
[27]  
Treatment recommendations in long-chain fatty acid oxidation defects: consensus from a workshop[J] . Spiekerkoetter U,Lindner M,Santer R,Grotzke M,Baumgartner M R,Boehles H,Das A,Haase C,Hennermann J B,Karall D,de Klerk H,Knerr I,Koch H G,Plecko B,R?schinger W,Schwab K O,Scheible D,Wijburg F A,Zschocke J,Mayatepek E,Wendel U.Journal of inherited metabolic disease . 2009 (4)
[28]  
Hypocitrullinemia in expanded newborn screening by LC–MS/MS is not a reliable marker for ornithine transcarbamylase deficiency[J] . C. Cavicchi,S. Malvagia,G. la Marca,S. Gasperini,M.A. Donati,E. Zammarchi,R. Guerrini,A. Morrone,E. Pasquini.Journal of Pharmaceutical and Biomedical Analysis . 2009 (5)
[29]  
The epidemiology of medium chain acyl-CoA dehydrogenase deficiency: an update[J] . Grosse Scott D,Khoury Muin J,Greene Carol L,Crider Krista S,Pollitt Rodney J.Genetics in medicine : official journal of the American College of Medical Genetics . 2006 (4)
[30]   Bezafibrate increases very-long-chain acyl-CoA dehydrogenase protein and mRNA expression in deficient fibroblasts and is a potential therapy for fatty acid oxidation disorders [J].
Djouadi, F ;
Aubey, F ;
Schlemmer, D ;
Ruiter, JPN ;
Wanders, RJA ;
Strauss, AW ;
Bastin, J .
HUMAN MOLECULAR GENETICS, 2005, 14 (18) :2695-2703